<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-04-09</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38590028/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Multifeature quantitative motor assessment of upper limb ataxia including drawing and reaching</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38590028-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    OBJECTIVE: Voluntary upper limb movements are an ecologically important yet insufficiently explored digital-motor outcome domain for trials in degenerative ataxia. We extended and validated the trial-ready quantitative motor assessment battery &ldquo;Q-Motor&rdquo; for upper limb movements with clinician-reported, patient-focused, and performance outcomes of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38590938/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38590938-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone <a href="https://bit.ly/3SSPX1C">https://bit.ly/3SSPX1C</a>. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592184/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Predictors of 2-Year Post-Discharge Mortality in Hospitalized Older Patients</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592184-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: PA, frailty, and underweight at hospital admission should be considered when evaluating long-term survival prognosis, establishing risk profiles, and developing personalized care pathways in acute hospital care of older &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592440/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">From the Assessment Section of the German Society for Orthopedics and Trauma Surgery in collaboration with the German Society for Neuroscientific Assessment (DGNB) : Assessment recommendations for musculoskeletal injury consequences in private accident insurance</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592440-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592485/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Pulse oximetry signal loss during hypoxic episodes in preterm infants receiving automated oxygen control</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592485-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The aim of this study was to analyze signal loss (SL) resulting from low signal quality of pulse oximetry-derived hemoglobin oxygen saturation (SpO(2)) measurements during prolonged hypoxemic episodes (pHE) in very preterm infants receiving automatic oxygen control (AOC). We did a post hoc analysis of a randomized crossover study of AOC, programmed to set FiO(2) to &ldquo;back-up FiO(2)&rdquo; during SL. In 24 preterm infants (median (interquartile range)) gestational age 25.3 (24.6 to 25.6) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592542/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses&#39; Health Studies</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592542-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Recreational physical activity was associated with lower breast cancer risk in both pre- and postmenopausal women, supporting recreational physical activity as an accessible, modifiable exposure associated with reduced breast cancer risk regardless of menopausal &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592668/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Odontoid Fracture with Accompanying Severe Atlantoaxial Instability in Elderly Patients-Analysis of Treatment, Adverse Events, and Outcome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592668-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    (1) Background: In elderly patients with type II odontoid fractures, accompanying severe atlantoaxial instability (AAI) is discussed as a marker possibly warranting more aggressive surgical therapy. This study aimed to characterize adverse events as well as the radiological and functional outcomes of surgical vs. conservative therapy in patients with odontoid fracture and AAI. (2) Methods: Patients aged 65 years and older with type II odontoid fracture and AAI treated were included. AAI &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8SSiC24E">ç»™æ¬§æ´²äººå‘é‚®ä»¶æ—¶ï¼Œæˆ‘ä¼šæŠŠåœ¨ç¾å›½ä¼šçœæ‰çš„å¼€å¤´ç»“å°¾çš„å˜˜å¯’é—®æš–å®¢å¥—è¯åŠ ä¸Šã€‚å› ä¸ºæˆ‘æƒ³æ¯•ç«Ÿä»–ä»¬æ˜¯æ¬§æ´²äººï¼Œä¸æ˜¯ç¾å›½äººã€‚è¿™è®©æˆ‘æƒ³èµ·äº†Successioné‡ŒGerriè¯´çš„ï¼Œä»–ä»¬ï¼ˆæ¬§...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8ssic24e/">
    
    
    
    
    
      
    
    ç»™æ¬§æ´²äººå‘é‚®ä»¶æ—¶ï¼Œæˆ‘ä¼šæŠŠåœ¨ç¾å›½ä¼šçœæ‰çš„å¼€å¤´ç»“å°¾çš„å˜˜å¯’é—®æš–å®¢å¥—è¯åŠ ä¸Šã€‚å› ä¸ºæˆ‘æƒ³æ¯•ç«Ÿä»–ä»¬æ˜¯æ¬§æ´²äººï¼Œä¸æ˜¯ç¾å›½äººã€‚è¿™è®©æˆ‘æƒ³èµ·äº†Successioné‡ŒGerriè¯´çš„ï¼Œä»–ä»¬ï¼ˆæ¬§æ´²äººï¼‰æ˜¯åœ¨å…¨æ°‘å…è´¹åŒ»ç–—ã€é«˜ç¦åˆ©çš„é˜³å…‰ä¸‹é•¿å¤§çš„ï¼›è€Œæˆ‘ä»¬ï¼ˆç¾å›½äººï¼‰æ˜¯åœ¨ç‹¼ç¾¤é‡Œé•¿å¤§çš„ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç¾å›½Â·æ—§é‡‘å±± (City of San Francisco)<!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8TV44LRV">å…³çˆ±è‡ªå·±ï¼Œä»æ­£è§†è‡ªå·±çš„ç²¾ç¥ç–¾æ‚£å¼€å§‹ã€‚æˆ‘è®²è¿‡å‡ æ¬¡æˆ‘å¾ˆå–œæ¬¢çœ‹Amy Schumerä¸»æ¼”çš„å–œå‰§Life &amp; Bethã€‚è¯¥å‰§ç¬¬äºŒå­£å…¨å­£å·²åœ¨Huluæ’­å‡ºï¼Œæˆ‘çœ‹åˆ°äº†ç¬¬4é›†ã€‚æˆ‘è§‰å¾—ç¬¬äºŒå­£æ¯”ç¬¬...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8tv44lrv/">
    
    
    
    
    
      
    
    å…³çˆ±è‡ªå·±ï¼Œä»æ­£è§†è‡ªå·±çš„ç²¾ç¥ç–¾æ‚£å¼€å§‹ã€‚æˆ‘è®²è¿‡å‡ æ¬¡æˆ‘å¾ˆå–œæ¬¢çœ‹Amy Schumerä¸»æ¼”çš„å–œå‰§Life &amp; Bethã€‚è¯¥å‰§ç¬¬äºŒå­£å…¨å­£å·²åœ¨Huluæ’­å‡ºï¼Œæˆ‘çœ‹åˆ°äº†ç¬¬4é›†ã€‚æˆ‘è§‰å¾—ç¬¬äºŒå­£æ¯”ç¬¬ä¸€å­£æ›´æœ‰è¶£ã€‚è™½ç„¶è¿™éƒ¨ç”µè§†å‰§ä»¥å–œå‰§å½¢å¼å±•ç°äº†å¾ˆå¤šæˆå¹´äººçš„æŒ£æ‰ï¼Œä½†å½’æ ¹ç»“åº•è¿™äº›æŒ£æ‰å¤§å¤šæ¥è‡ªäºç«¥å¹´æ—¶çš„traumaï¼ˆç²¾ç¥åˆ›ä¼¤ï¼‰ï¼Œå°¤å…¶æ˜¯è¢«bullyï¼ˆéœ¸å‡Œï¼‰çš„ç»å†ã€‚æ›´é‡è¦çš„æ˜¯ï¼Œè¿™ä¸€å­£çªå‡ºäº†ASDï¼ˆè‡ªé—­ç—‡ï¼‰å¯¹æ‚£è€…è‡ªå·±å’Œå®¶äººçš„å·¨å¤§å½±å“ï¼Œè¿™æ›´åƒæ˜¯Amy Schumeråˆ©ç”¨è‡ªå·±çš„å¹³å°æ¨å¹¿çš„ä¸€é¡¹å…¬ç›Šé¡¹ç›®ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->è¿™äº›å¹´ï¼Œåœ¨å¾ˆå¤šå‘è¾¾å›½å®¶ï¼Œæ™®é€šäººç¾¤å¯¹äºç²¾ç¥ç–¾ç—…çš„æ­£è§†ç¨‹åº¦è¶Šæ¥è¶Šé«˜ã€‚åœ¨ç¾å›½ï¼Œæ¯å¹´5æœˆæ˜¯Mental Health Awareness Monthï¼ˆç²¾ç¥å¥åº·å…¬ç›Šæœˆï¼‰ã€‚å»å¹´5æœˆï¼ŒBidenæ”¿åºœä¸“é—¨é‚€ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8UqCd3zb">aiæ— æ³•å–ä»£äººç±»çš„è¯æ®æœ‰äº† - è½¬å‘ @ååœºé¢All:&amp;ensp;å¥½ç‹‚é‡çš„åŠ¨ç”»â€¦â€¦ å¥½æ”¾è‚†çš„å‰§æƒ…â€¦â€¦ ååœºé¢Allçš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8uqcd3zb/">
    
    
    
    
    
      
    
    aiæ— æ³•å–ä»£äººç±»çš„è¯æ®æœ‰äº†<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@ååœºé¢All<!-- raw HTML omitted -->:â€‚å¥½ç‹‚é‡çš„åŠ¨ç”»â€¦â€¦ å¥½æ”¾è‚†çš„å‰§æƒ…â€¦â€¦ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ååœºé¢Allçš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax2.sinaimg.cn/orj480/007ad9bhly1hoh1n57fmq">https://tvax2.sinaimg.cn/orj480/007ad9bhly1hoh1n57fmq</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8XXaCUAh">å¤ªæ˜åªšäº†ï¼Œé€‚åˆæ‹¯æ•‘æˆ‘è¿™ç§é˜´æš—æ‰¹[æ˜¥æ¸¸å®¶æ—] - è½¬å‘ @Koreaç§æœé›†:&amp;ensp;å®‹é›¨ç¦ INSæ›´æ–°ğŸƒğŸï¸ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8xxacuah/">
    
    
    
    
    
      
    
    å¤ªæ˜åªšäº†ï¼Œé€‚åˆæ‹¯æ•‘æˆ‘è¿™ç§é˜´æš—æ‰¹<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@Koreaç§æœé›†<!-- raw HTML omitted -->:â€‚å®‹é›¨ç¦ INSæ›´æ–°ğŸƒğŸï¸ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8SUM3fvS">é”™çš„ä¸æ˜¯æˆ‘ï¼Œæ˜¯è¿™ä¸ªä¸–ç•ŒğŸ‘¿ğŸ‘¿ğŸ‘¿ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8sum3fvs/">
    
    
    
    
    
      
    
    é”™çš„ä¸æ˜¯æˆ‘ï¼Œæ˜¯è¿™ä¸ªä¸–ç•ŒğŸ‘¿ğŸ‘¿ğŸ‘¿ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8TNYn6Vz">#å¾®åšå¤´åƒæŒ‚ä»¶# æˆ‘æ­£åœ¨ä½¿ç”¨â€œæ„Ÿæ©èŠ‚â€å¤´åƒæŒ‚ä»¶ï¼Œä½ ä¹Ÿå¿«æˆ´ä¸Šå§ï¼ å¤´åƒæŒ‚ä»¶ï¼šæ„Ÿæ©èŠ‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8tnyn6vz/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted -->#å¾®åšå¤´åƒæŒ‚ä»¶#<!-- raw HTML omitted --><!-- raw HTML omitted --> æˆ‘æ­£åœ¨ä½¿ç”¨â€œæ„Ÿæ©èŠ‚â€å¤´åƒæŒ‚ä»¶ï¼Œä½ ä¹Ÿå¿«æˆ´ä¸Šå§ï¼ <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_web_default.png%22">https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_web_default.png&quot;</a> referrerpolicy=&ldquo;no-referrer&rdquo; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8TOXAlwh">æ„Ÿè§‰è¿™å­£èŠ‚å‡ºé—¨éœ€è¦ä¿©å£ç½©äº†ï¼Œå®¤å¤–å¤–ç§‘å£ç½©ï¼Œå®¤å†…N95[äºŒå“ˆ]ğŸ‘¿</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8toxalwh/">
    
    
    
    
    
      
    
    æ„Ÿè§‰è¿™å­£èŠ‚å‡ºé—¨éœ€è¦ä¿©å£ç½©äº†ï¼Œå®¤å¤–å¤–ç§‘å£ç½©ï¼Œå®¤å†…N95<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ğŸ‘¿  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8VZAhSFe">å¬åˆ°ä¸€ä¸ªå»ºè®®ï¼šåº§å­è¿˜æ£‹å¤´ä¸‹ä¸¤æ—¥åˆ¶</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8vzahsfe/">
    
    
    
    
    
      
    
    å¬åˆ°ä¸€ä¸ªå»ºè®®ï¼š<!-- raw HTML omitted -->åº§å­è¿˜æ£‹å¤´ä¸‹ä¸¤æ—¥åˆ¶  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8W8ElCD4">æ„Ÿè°¢å¤§è‡ªç„¶çš„é¦ˆèµ  [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8w8elcd4/">
    
    
    
    
    
      
    
    æ„Ÿè°¢å¤§è‡ªç„¶çš„é¦ˆèµ  <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8XjK1L1n">æ•™å¤§è€çˆ·ï¼šshrimpä»–ï¼šç¡puï¼Œç©pu</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8xjk1l1n/">
    
    
    
    
    
      
    
    æ•™å¤§è€çˆ·ï¼šshrimp<!-- raw HTML omitted -->ä»–ï¼šç¡puï¼Œç©pu  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Ua52KIZ">ç¹¼æŠ«è–©ã€ç…é¤ƒã€é¹½éºµåŒ…å¾Œçš„æ–°ç ”ç™¼æ–¹å‘[äºŒå“ˆ] - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.09 11:27ã€Œå˜¿å˜¿å˜¿ã€æƒ³åšæ—¥å¼èœé¥­ï¼æƒ³åƒï¼æƒ³å˜å¾—å¥åº·...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8ua52kiz/">
    
    
    
    
    
      
    
    ç¹¼æŠ«è–©ã€ç…é¤ƒã€é¹½éºµåŒ…å¾Œçš„æ–°ç ”ç™¼æ–¹å‘<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/tim">https://n.sinaimg.cn/photo/5213b46e/20180926/tim</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8VQkeZ21">ç´—æœˆç·’ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8vqkez21/">
    
    
    
    
    
      
    
    ç´—æœˆç·’ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8VYXjMQi">æ—¥é£¯æ¶å…ˆé–‹å…§å°ç”Ÿå¯«ï¼Œä¹…ä¿çœŸå¥½çœ‹ï¼ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8vyxjmqi/">
    
    
    
    
    
      
    
    æ—¥é£¯æ¶å…ˆé–‹å…§å°ç”Ÿå¯«ï¼Œä¹…ä¿çœŸå¥½çœ‹ï¼ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Ydq0gPN">è½¬å‘å¾®åš - è½¬å‘ @äº•ä¸Šè¯¶å˜¿å­:&amp;ensp;æ°‘å›½è°æˆ˜ç”µå½±å¥³äºŒå· [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8ydq0gpn/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@äº•ä¸Šè¯¶å˜¿å­<!-- raw HTML omitted -->:â€‚æ°‘å›½è°æˆ˜ç”µå½±å¥³äºŒå· <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8Ts13lcF">äº•å±±ï¼šä¸€ç›´ç›¯ç€æ£‹ç›˜å®åœ¨æ˜¯å¤ªç´¯äº†ï¼Œå‰å‡ å¤©å»çœ‹äº†çœ‹æ¨±èŠ±ã€‚æ¨±èŠ±å‡ ä¹ç››å¼€ï¼Œäººä¹Ÿéå¸¸å¤š#å›´æ£‹#å›´æ£‹ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8ts13lcf/">
    
    
    
    
    
      
    
    äº•å±±ï¼šä¸€ç›´ç›¯ç€æ£‹ç›˜å®åœ¨æ˜¯å¤ªç´¯äº†ï¼Œå‰å‡ å¤©å»çœ‹äº†çœ‹æ¨±èŠ±ã€‚<!-- raw HTML omitted -->æ¨±èŠ±å‡ ä¹ç››å¼€ï¼Œäººä¹Ÿéå¸¸å¤š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å›´æ£‹<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8TH6yMba">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.09 11:27ã€Œå˜¿å˜¿å˜¿ã€æƒ³åšæ—¥å¼èœé¥­ï¼æƒ³åƒï¼æƒ³å˜å¾—å¥åº·ï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8th6ymba/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8WiuhBwm">ä¹…ä¿å²ç»ªé‡Œvia.eagles_shop [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8wiuhbwm/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.eagles_shop <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hokq9xhr">https://tvax1.sinaimg.cn/large/006z6nxLgy1hokq9xhr</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8WiyFaen">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.09 18:49ã€Œå™—ã€æœ€è¿‘ç«‹é©¬å°±è‚šå­é¥¿äº†å•Šã€‚ä½†è”¬èœå´æ€ä¹ˆéƒ½ç…®ä¸ç†Ÿå•Šã€‚æ˜æ˜ç›–ä¸Šäº†ç›–å­è¯¶ã€œè‚šå­é¥¿äº†å•Šã€ã€ã€</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8wiyfaen/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8WnY6DTq">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.09 18:52ã€Œå•ªã€åƒè”¬èœã€‚æœ€è¿‘éƒ½æ²¡æ€ä¹ˆåƒè”¬èœè¦åƒå¥½å¤šå¥½å¤šå¥½å¤šè”¬èœã€‚ä½ å–œæ¬¢ä»€ä¹ˆè”¬èœå•Šå•Šï¼ï¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8wny6dtq/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8VPW0ag5">æŸ¯æ´#2024lgæ¯é€‰æ‹”èµ›##èµ›äº‹é¢„å‘Š# æŸ¯æ´ä¹æ®µæ‰§é»‘255æ‰‹ä¸­ç›˜èƒœæç»´æ¸…ä¹æ®µã€‚ç»§ç»­åŠ æ²¹ï¼[åŠ æ²¹][åŠ æ²¹][åŠ æ²¹][èµ¢ç‰›å¥¶][èµ¢ç‰›å¥¶][èµ¢ç‰›å¥¶] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8vpw0ag5/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#2024 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8WwBrX3s">æŸ¯æ´#2024lgæ¯é€‰æ‹”èµ›##èµ›äº‹é¢„å‘Š# ç¬¬29å±ŠLGæ¯ä¸–ç•Œå›´æ£‹æ£‹ç‹æˆ˜ä¸­å›½ä»£è¡¨é€‰æ‹”èµ›ç¬¬ä¸€é˜¶æ®µç¬¬äºŒè½®å°†äºæ˜å¤©ä¸­åˆåäºŒç‚¹åŠåœ¨æµ™æ±Ÿè¡¢å·å—å­”è§‚å ‚é…’åº—è¿›è¡Œï¼ŒæŸ¯æ´ä¹æ®µå¯¹é˜µå¥½æœ‹å‹...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8wwbrx3s/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/pin/1761134909119123456">é‡å­ä½å‘å¸ƒäº†æƒ³æ³•: å¸¦é¢†å›¢é˜Ÿå¼€å‘ChatExcelã€ChatLawçš„åŒ—äº¬å¤§å­¦æ·±åœ³ç ”ç©¶ç”Ÿé™¢åŠ©ç†æ•™æˆè¢ç²’ ç¡®è®¤å‚ä¸ #ä¸­å›½AIGCäº§ä¸šå³°ä¼š ï¼ğŸ”¥&lt;br&gt;&lt;br&gt;è¢ç²’ï¼ŒåŒ—äº¬å¤§å­¦åšå£«ç”Ÿå¯¼å¸ˆã€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-pin-1761134909119123456/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691499895">é‡å­ä½å‘è¡¨äº†æ–‡ç« : OpenAIåˆ›å§‹å¤§ç¥æ‰‹æ“åƒè¡ŒCä»£ç è®­ç»ƒGPTï¼Œé™„PyTorchè¿ç§»æ•™ç¨‹</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691499895/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691508465">é‡å­ä½å‘è¡¨äº†æ–‡ç« : åŒ—å¤§å¼€æºæœ€å¼ºaiXcoder-7Bä»£ç å¤§æ¨¡å‹ï¼èšç„¦çœŸå®å¼€å‘åœºæ™¯ï¼Œä¸“ä¸ºä¼ä¸šç§æœ‰éƒ¨ç½²è®¾è®¡</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691508465/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691509851">é‡å­ä½å‘è¡¨äº†æ–‡ç« : é¦™æ¸¯å¤§æ¨¡å‹å…¬å¸Weitu AIé¦–ç§€ï¼Œæ‰“é€ å¤šæ¨¡æ€Nativeçš„æŠ€æœ¯å’Œäº§å“</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691509851/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691510637">é‡å­ä½å‘è¡¨äº†æ–‡ç« : GPT-4ä¸€çœ¼çœ‹ç©¿è®ºæ–‡ä¼šä¸ä¼šæ’¤ç¨¿ï¼š7000ç¯‡å®æµ‹å‡†ç¡®ç‡é«˜è¾¾95%ï½œäººå¤§æµ™å¤§</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691510637/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691543378">é‡å­ä½å‘è¡¨äº†æ–‡ç« : åˆšåˆšï¼Œåˆæœ‰20äº¿å·¨æ¬¾ç ¸å‘AIï¼Œäº§ä¸šåœºæ™¯é‡Œçš„AGI</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691543378/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691546846">é‡å­ä½å‘è¡¨äº†æ–‡ç« : WPS 365å…¨æ–°å‘å¸ƒï¼Œå¼€å¯ä¼ä¸šä¸€ç«™å¼AIåŠå…¬</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691546846/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20240408180459&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20240408180459-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20240409180647&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20240409180647-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240408180525&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240408180525-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240409180657&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240409180657-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584857/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Usage Behaviour and Adoption Criteria for Mobile Health Solutions in Patients with Chronic Diseases in Gastroenterology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584857-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Mobile Health (mHealth) applications allow for new possibilities and opportunities in patient care. Their potential throughout the whole patient journey is undisputed. However, the eventual adoption by patients depends on their acceptance of and motivation to use mHealth applications as well as their adherence. Therefore, we investigated the motivation and drivers of acceptance for mHealth and developed an adapted model of the Unified Theory of Acceptance and Use of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584883/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584883-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: With excellent long-term treatment outcomes and minimal associated toxicities, our results showed that LDR brachytherapy can be an effective treatment of choice in younger &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38585372/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38585372-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TV(MR+FET) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38586081/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter &lt;em&gt;SMILE&lt;/em&gt; phase II trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38586081-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without any major negative impact on quality of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38586301/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38586301-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587186/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587186-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    AT-rich interaction domain protein 1A (ARID1A), a SWI/SNF chromatin remodeling complex subunit, is frequently mutated across various cancer entities. Loss of ARID1A leads to DNA repair defects. Here, we show that ARID1A plays epigenetic roles to promote both DNA double-strand breaks (DSBs) repair pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR). ARID1A is accumulated at DSBs after DNA damage and regulates chromatin loops formation by recruiting RAD21 and CTCF &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587213/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Evolution of Pyoderma Gangrenosum</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587213-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587218/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">unDOCumented - On Becoming an Undocumented Doctor in the United States</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587218-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587233/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587233-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587237/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Empagliflozin after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587237-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587237/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Empagliflozin after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587237-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587239/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587239-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587239/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587239-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587241/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587241-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (â‰¥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587241/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587241-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (â‰¥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587247/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587247-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587247/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587247-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Shooting the Messenger to Treat Hypertriglyceridemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Shooting the Messenger to Treat Hypertriglyceridemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587249/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587249-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587249/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587249-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587250/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587250-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587250/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587250-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587253/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587253-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587253/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587253-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587254/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587254-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587254/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587254-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587255/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Routine Beta-Blockers in Secondary Prevention - On Injured Reserve</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587255-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587255/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Routine Beta-Blockers in Secondary Prevention - On Injured Reserve</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587255-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587261/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587261-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with severe aortic stenosis and a small aortic annulus who underwent TAVR, a self-expanding supraannular valve was noninferior to a balloon-expandable valve with respect to clinical outcomes and was superior with respect to bioprosthetic-valve dysfunction through 12 months. (Funded by Medtronic; SMART ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587261/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587261-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with severe aortic stenosis and a small aortic annulus who underwent TAVR, a self-expanding supraannular valve was noninferior to a balloon-expandable valve with respect to clinical outcomes and was superior with respect to bioprosthetic-valve dysfunction through 12 months. (Funded by Medtronic; SMART ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587317/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587317-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Microsatellite-unstable (MSI) cancers require WRN helicase to resolve replication stress due to expanded DNA (TA)n-dinucleotide repeats. WRN is a promising synthetic lethal target for MSI tumours, and WRN inhibitors are in development. Here, we used CRISPR-Cas9 base editing to map WRN residues critical for MSI cells, validating the helicase domain as the primary drug target. Fragment-based screening led to the development of potent and highly selective WRN helicase covalent inhibitors. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587386/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Differentiation and Characterization of Osteoclasts from Human Induced Pluripotent Stem Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587386-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    This protocol details the propagation and passaging of human iPSCs and their differentiation into osteoclasts. First, iPSCs are dissociated into a single-cell suspension for further use in embryoid body induction. Following mesodermal induction, embryoid bodies undergo hematopoietic differentiation, producing a floating hematopoietic cell population. Subsequently, the harvested hematopoietic cells undergo a macrophage colony-stimulating factor maturation step and, finally, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587564/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">The role of coronary artery disease in lung transplantation: a propensity-matched analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587564-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In this cohort, relevant CAD was not associated with worse outcomes and should therefore not be considered a contraindication for LuTx. Nonetheless, cardiovascular events in CAD patients highlight the necessity of control of cardiovascular risk factors and a structured cardiac &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587632/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Congenital diaphragmatic hernia : Imaging-from diagnosis to aftercare</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587632-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    STANDARD RADIOLOGICAL METHODS: Fetal: Ultrasound and magnetic resonance imaging (MRI); postnatal: conventional Xâ€‘ray diagnostics, computed tomography (CT) and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587854/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587854-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND RELEVANCE: This nonrandomized controlled trial demonstrated effectiveness of newborn screening for infants with SMA in the real-world setting. Functional outcomes and thus the response to treatment were significantly better in the newborn screening cohort compared to the unscreened clinical symptom onset &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587995/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587995-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with STEMI or very-high-risk NSTEMI and multivessel coronary artery disease, FFR-guided complete revascularization was not shown to result in a lower risk of a composite of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only PCI at 4.8 years. (Funded by the Swedish Research Council and others; FULL REVASC ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588006/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588006-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588008/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Another Early Win for TAVI in Low-Risk Patients</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588008-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588025/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Transcatheter or Surgical Treatment of Aortic-Valve Stenosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588025-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with severe aortic stenosis at low or intermediate surgical risk, TAVI was noninferior to SAVR with respect to death from any cause or stroke at 1 year. (Funded by the German Center for Cardiovascular Research and the German Heart Foundation; DEDICATE-DZHK6 ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240409180636&amp;v=2.18.0.post9&#43;e462414">Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588489-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240409180636-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in bone marrow/blood (BCP acute lymphoblastic leukemia, BCP-ALL) or less common in extramedullary tissue (BCP lymphoblastic lymphoma, BCP-LBL). Although both presentations are similar in morphology and immunophenotype, molecular studies are virtually restricted to BCP-ALL so far. The lack of molecular studies on BCP-LBL is due to its rarity and the restriction to small, mostly &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588654/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Indicated Stress Prevention Addressing Adolescents with High Stress Levels Based on Principles of Acceptance and Commitment Therapy: A Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588654-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Indicated prevention, especially when based on the principles of ACT and CBT, seems efficient in significantly decreasing stress in adolescents with increased &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588693/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">The value of contrast-enhanced ultrasound in percutaneous biopsy of retroperitoneal masses</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588693-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Percutaneous CEUS-guided biopsy is a safe procedure with a high diagnostic yield and a low complication &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588756/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">The fentanyl-specific antibody FenAb024 can shield against carfentanil effects</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588756-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The surge in opioid-related deaths, driven predominantly by fentanyl and its synthetic derivatives, has become a critical public health concern, which is particularly evident in the United States. While the situation is less severe in Europe, the European Monitoring Centre for Drugs and Drug Addiction reports a rise in drug overdose deaths, with emerging concerns about the impact of fentanyl-related molecules. Synthetic opioids, initially designed for medical use, have infiltrated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588862/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Reply to: Kavsak et al. The clinical chemistry score (CCS) achieves the highest efficacy when assessed with the 99% sensitivity benchmark for myocardial infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588862-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588880/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240409180657&amp;v=2.18.0.post9&#43;e462414">INSPIRED Symposium Part 5: Expanding the Use of CAR T cells in Children and Young Adults</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588880-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240409180657-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute lymphoblastic leukemia (ALL). Expanding this success to other hematologic and solid malignancies is an area of active research and, although challenges remain, novel solutions have led to significant progress over the past decade. Ongoing clinical trials for CAR T cell therapy for T cell malignancies and acute &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588929/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588929-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with AMI, severity of LV dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588930/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588930-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588993/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">An International Multicenter Cohort Study on Implantable Cardioverter Defibrillators for the Treatment of Symptomatic Children with Catecholaminergic Polymorphic Ventricular Tachycardia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588993-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: SCD events occurred only in the no ICD group, in those not on optimal medical therapy. ICD patients had a high risk of appropriate and inappropriate shocks, which may be reduced with appropriate device programming. Severe ICD complications were common and risks versus benefits of ICDs need to be &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589007/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20240409180640&amp;v=2.18.0.post9&#43;e462414">A muti-modal feature fusion method based on deep learning for predicting immunotherapy response</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589007-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20240409180640-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Immune checkpoint therapy (ICT) has greatly improved the survival of cancer patients in the past few years, but only a small number of patients respond to ICT. To predict ICT response, we developed a multi-modal feature fusion model based on deep learning (MFMDL). This model utilizes graph neural networks to map gene-gene relationships in gene networks to low dimensional vector spaces, and then fuses biological pathway features and immune cell infiltration features to make robust predictions &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589480/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Exploring the microbial savanna: predator-prey interactions in the soil</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589480-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589601/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Maternal diabetes and risk of attention-deficit/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother-child pairs</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589601-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Previous studies report an association between maternal diabetes mellitus (MDM) and attention-deficit/hyperactivity disorder (ADHD), often overlooking unmeasured confounders such as shared genetics and environmental factors. We therefore conducted a multinational cohort study with linked mother-child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between different MDM (any MDM, gestational diabetes mellitus (GDM) and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589615/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Atmospheric pressure field desorption-trapped ion mobility-mass spectrometry coupling</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589615-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    While field ionization (FI) and field desorption (FD) are established soft vacuum ionization methods in mass spectrometry (MS), the technique of atmospheric pressure field desorption (APFD) has only recently been added to the repertoire. Similar to FI and FD, APFD can yield both positive even-electron ions of highly polar or ionic compounds and positive molecular ions, M^(+â€¢), e.g., of polycyclic aromatic compounds. Thus, a dedicated APFD source assembly has been constructed and demonstrated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589793/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20240409180647&amp;v=2.18.0.post9&#43;e462414">Deep learning-based image annotation for leukocyte segmentation and classification of blood cell morphology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589793-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20240409180647-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The research focuses on the segmentation and classification of leukocytes, a crucial task in medical image analysis for diagnosing various diseases. The leukocyte dataset comprises four classes of images such as monocytes, lymphocytes, eosinophils, and neutrophils. Leukocyte segmentation is achieved through image processing techniques, including background subtraction, noise removal, and contouring. To get isolated leukocytes, background mask creation, Erythrocytes mask creation, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589856/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589856-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1-3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20-40% and recurrence rates are up to ~ 75%(4-6). Up to ~ 40% of patients relapse within 12 months after resection, and half of these patient will &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589879/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Fasting upregulates the monocarboxylate transporter MCT1 at the rat blood-brain barrier through PPAR Î´ activation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589879-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Altogether, our study shows that fasting affects a selected set of BBB transporters which does not include the main drug efflux transporters. Moreover, we describe a previously unknown selective adaptive response of the brain vasculature to fasting which involves PPAR Î´ and is responsible for the up-regulation of MCT1 expression and activity. Our study opens new perspectives for the metabolic manipulation of the BBB in the healthy or diseased &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589974/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Clinical profiles of adolescent personality pathology: a latent structure examination of the Semi-Structured Interview for Personality Functioning DSM-5 (STiP-5.1) in a help-seeking sample</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589974-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: A complex model incorporating both dimensional and categorical components most adequately describes the latent structure of the STiP-5.1 in our adolescent sample. We conclude that Criterion A provides clinically useful information beyond severity (as a dimensional continuum) alone, and that the hybrid model found for personality functioning in our sample warrants further attention. Findings can help to parse out clinical heterogeneity in personality pathology in adolescents, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8JKrspzK">Samâ€™s Chowderï¼ŒSFç‰¹è‰²ä½³è‚´Cioppinoç‰¹åˆ«ç¾å‘³ã€‚è¿™é‡Œæ˜¯ç¾æ™¯&#43;ç¾é£Ÿã€‚è¿™äº›å¹´ï¼Œæˆ‘ä¸æˆ‘è®¤è¯†çš„å¾ˆå¤šhiring managerå’Œrecruiterä»¥åŠæˆ‘è‡ªå·±çš„career coachèŠå¤©ï¼Œæˆ‘é—®ä»–ä»¬æ¹¾...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8jkrspzk/">
    
    
    
    
    
      
    
    Samâ€™s Chowderï¼ŒSFç‰¹è‰²ä½³è‚´Cioppinoç‰¹åˆ«ç¾å‘³ã€‚è¿™é‡Œæ˜¯ç¾æ™¯+ç¾é£Ÿã€‚è¿™äº›å¹´ï¼Œæˆ‘ä¸æˆ‘è®¤è¯†çš„å¾ˆå¤šhiring managerå’Œrecruiterä»¥åŠæˆ‘è‡ªå·±çš„career coachèŠå¤©ï¼Œæˆ‘é—®ä»–ä»¬æ¹¾åŒº/ç¡…è°·æœ€å¥½çš„æ˜¯ä»€ä¹ˆï¼Œä»–ä»¬éƒ½ä¸çº¦è€ŒåŒåœ°å›ç­”talent poolã€‚æˆ‘å¾ˆå¤šä¸œæµ·å²¸æ¯•ä¸šçš„åŒäº‹éƒ½æ„¿æ„æ¬åˆ°è¿™é‡Œã€‚è¿™è®©æˆ‘æƒ³èµ·äº†2010å¹´ç”µå½±The Social Networkï¼Œå½±ç‰‡ä¸­Saverinå¯¹åœ¨Cambridgeå†°å¤©é›ªåœ°ä¸­çš„Zuckerbergè¯´ï¼Œä½ å¿…é¡»è¦åˆ°è¿™é‡Œæ¥åˆ›ä¸šï¼Œè¿™é‡Œå¤ªä¸ä¸€æ ·äº†ã€‚ç„¶åZuckerbergä¸€æ¥ä»–ä»¬å°±è·³è¿›äº†æˆ·å¤–æ¸¸æ³³æ± ã€‚å››å­£æ’æ¸©+å¤ªå¹³æ´‹å¤§æ´‹æ™¯è‰²æ˜¯åˆ›ä¸šè€…å¤©å ‚ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_location_default.png%22">https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_location_default.png&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/O8Ky9p88i">è¿™å­©å­å¯ä»¥ï¼Œæœ‰å‰é€”ï¼ - è½¬å‘ @ç‹å‡¯ä¼¦KW:&amp;ensp;æ²¡æƒ³åˆ°ï¼Œåˆšä¹°çš„ä¹¦æˆ‘è¿˜æ²¡ç¿»ï¼Œè¢«æˆ‘8å²çš„å„¿å­åœ¨é£æœºä¸Šçœ‹å®Œäº†ã€‚æ•´ä¸ªæ¸…æ˜å‡æœŸä»–ç¿»äº†ä¸ä¸‹ä¸‰éï¼Œè¾¹çœ‹è¾¹å“ˆå“ˆå¤§ç¬‘ï¼Œè¿˜è·Ÿæˆ‘...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-o8ky9p88i/">
    
    
    
    
    
      
    
    è¿™å­©å­å¯ä»¥ï¼Œæœ‰å‰é€”ï¼<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@ç‹å‡¯ä¼¦KW<!-- raw HTML omitted -->:â€‚æ²¡æƒ³åˆ°ï¼Œåˆšä¹°çš„ä¹¦æˆ‘è¿˜æ²¡ç¿»ï¼Œè¢«æˆ‘8å²çš„å„¿å­åœ¨é£æœºä¸Šçœ‹å®Œäº†ã€‚æ•´ä¸ªæ¸…æ˜å‡æœŸä»–ç¿»äº†ä¸ä¸‹ä¸‰éï¼Œè¾¹çœ‹è¾¹å“ˆå“ˆå¤§ç¬‘ï¼Œè¿˜è·Ÿæˆ‘ç©å°è¯´å†…å®¹é—®ç­”ï¼Œå¯è§æ˜¯çœŸçˆ±ã€‚æˆ‘æ˜¨æ™šè¶å¨ƒç¡ç€ç»ˆäºç†¬å¤œçœ‹å®Œäº†ï¼Œè„‘å­é‡Œä¸ç”±è‡ªä¸»åœ°å›è¡ç€èˆŒå°–ä¸Šçš„é…ä¹å’Œé…éŸ³ã€‚å¤ªå¥½çœ‹äº† <!-- raw HTML omitted -->@é©¬ä¼¯åº¸<!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/731202f7gy1hoj4lh6uf7j22c03401ky.jpg%22">https://tvax1.sinaimg.cn/large/731202f7gy1hoj4lh6uf7j22c03401ky.jpg&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/O8M0byAVR">é£å“¥éš¾å¾—å‡ºä¹¦ï¼Œæˆ‘éšä¸ªä»½å­[æ‰“call]ç»™ä¸­å¥–çš„æœ‹å‹ä¸€äººåŠ é€ä¸€æœ¬ã€Šé£Ÿå—ä¹‹å¾’ã€‹ - è½¬å‘ @æœˆå®…fei:&amp;ensp;å„ä½äº²äººï¼Œä»Šå¤©æ˜¯ä¸æ˜¯ä¹Ÿæ²¡ä»€ä¹ˆä¸Šç­çš„çƒ­æƒ…ï¼Ÿé‚£æˆ‘æ­£å¥½è·Ÿå¤§å®¶è¯´ä¸ª...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-o8m0byavr/">
    
    
    
    
    
      
    
    é£å“¥éš¾å¾—å‡ºä¹¦ï¼Œæˆ‘éšä¸ªä»½å­<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç»™ä¸­å¥–çš„æœ‹å‹ä¸€äººåŠ é€ä¸€æœ¬ã€Šé£Ÿå—ä¹‹å¾’ã€‹<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æœˆå®…fei<!-- raw HTML omitted -->:â€‚å„ä½äº²äººï¼Œä»Šå¤©æ˜¯ä¸æ˜¯ä¹Ÿæ²¡ä»€ä¹ˆä¸Šç­çš„çƒ­æƒ…ï¼Ÿé‚£æˆ‘æ­£å¥½è·Ÿå¤§å®¶è¯´ä¸ªäº‹å„¿~<!-- raw HTML omitted -->æˆ‘çš„æ–°ä¹¦ï¼Œç§‘å¹»å°è¯´ã€Šé‡å¯é»æ˜ã€‹è¿™ä¸ªæœˆå‡ºç‰ˆäº†ã€‚ä¸»è¦æ˜¯è®²åœ¨å‡ å¹´åçš„æœªæ¥æŸä¸€å¤©ï¼Œå¤©ä¸Šçªç„¶å‡ºç°äº†å¤§åå­—ï¼Œåœ°ä¸Šè¹¦å‡ºæ¥è®¸å¤šè¶…èƒ½åŠ›è€…ï¼Œçœ¼ç…ç€å…¨ä¸–ç•Œéƒ½ä¸å¤§å¦™ï¼Œè¿™æ—¶å€™æœ‰ä¸€ä¸ªåœ¨ç¾å›½å‡ºå·®ã€å¹³å¹³æ— å¥‡çš„ä¸­å›½å¦‡å¥³ç«™äº†å‡ºæ¥ï¼Œä¸ºäº†å›å›½ä¸å®¶äººå›¢èšï¼Œä¸€è·¯å¸¦ç€åŒäº‹å’Œè·¯ä¸Šæ¡åˆ°ï¼ˆâ€¦â€¦ï¼‰çš„é˜Ÿå‹ä»¬ï¼Œæ€ç©¿äº†åŠä¸ªä¸œæµ·å²¸ï¼ˆå¥½å§ä¸‰åˆ†ä¹‹ä¸€ä¸ªï¼‰ï¼Œå»ç»™å¤§é­”ç‹ä¸€ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8KlImb30">â€œæˆ‘å¿˜å•¦hhhâ€[è‹¦æ¶©][è‹¦æ¶©][è‹¦æ¶©]å¥½å¯çˆ±çš„ç‹—[è‹¦æ¶©][è‹¦æ¶©][è‹¦æ¶©] - è½¬å‘ @ç™½å®¢ä¸‡äº‹å±‹:&amp;ensp;cucn201ç™½å®¢ç™½å®¢ Bossã€Šæ—©ç‚¹æ‰ä¼šèµ¢ã€‹ä¹‹å¼€å·¥å°è®°ğŸ“¹ç¥å¤§å®¶å‘¨ä¸€å¿«ä¹ï¼ ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8klimb30/">
    
    
    
    
    
      
    
    â€œæˆ‘å¿˜å•¦hhhâ€<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;/s &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8Oz8x1XU">å•Šå•Šå•Šç¬‘å¾— - è½¬å‘ @Wink-å°ç‹—:&amp;ensp;ä»Šå¤©åˆ·åˆ°åˆ«äººçš„ï¼Œæ€ä¹ˆæ²¡æœ‰äººç©è¿™ä¸ªæ¢—ï¼Ÿè™½ç„¶æˆ‘æ„Ÿè§‰è¿‡æ—¶äº†[åç¬‘] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8oz8x1xu/">
    
    
    
    
    
      
    
    å•Šå•Šå•Šç¬‘å¾—<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@Wink-å°ç‹—<!-- raw HTML omitted -->:â€‚ä»Šå¤©åˆ·åˆ°åˆ«äººçš„ï¼Œæ€ä¹ˆæ²¡æœ‰äººç©è¿™ä¸ªæ¢—ï¼Ÿè™½ç„¶æˆ‘æ„Ÿè§‰è¿‡æ—¶äº†<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8NI5pLQU">å’–å•¡åŠ å¥¥ç¾æ‹‰å”‘ï¼Œèƒ½ä¸èƒ½ç²¾ç¥ç€æ²»äº†èƒƒç—…[æ€’]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8ni5plqu/">
    
    
    
    
    
      
    
    å’–å•¡åŠ å¥¥ç¾æ‹‰å”‘ï¼Œèƒ½ä¸èƒ½ç²¾ç¥ç€æ²»äº†èƒƒç—…<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8PWusSnI">æƒ³èµ·äº†ä¸‰åå¹´å‰çš„äº‹æƒ…</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8pwussni/">
    
    
    
    
    
      
    
    æƒ³èµ·äº†ä¸‰åå¹´å‰çš„äº‹æƒ…  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8OAeDEwV">å¤´å‘ï¼ŒçœŸçš„å¥½é•¿äº† - è½¬å‘ @å±±ä¸‹ç¾æœˆæ•™ä¼š:&amp;ensp;å±±ä¸‹ç¾æœˆ ä¹ƒæœ¨å‚46ã€å¤æ¡œã€Music Video å±±ä¸‹ç¾æœˆæ•™ä¼šçš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8oaedewv/">
    
    
    
    
    
      
    
    å¤´å‘ï¼ŒçœŸçš„å¥½é•¿äº†<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å±±ä¸‹ç¾æœˆæ•™ä¼š<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å±±ä¸‹ç¾æœˆ<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->ä¹ƒæœ¨å‚46ã€å¤æ¡œã€Music Video<!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo.com/show?fid=1034:5020992972718092%22">https://video.weibo.com/show?fid=1034:5020992972718092&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Od69GgS">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.08 19:10ã€Œå‘œå‘¼å‘¼ã€æ˜¯æƒ³åŠªåŠ›çš„æ—¥å­å‘¢ã€œè™½ç„¶å¤©æ°”ä¸å¤ªç¨³å®šï¼Œä½†ä¸è¦è¢«è¿™å·¦å³ï¼Œè†å¬å–œæ¬¢çš„...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8od69ggs/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/searc">https://m.weibo.cn/searc</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Od9AHED">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œvia. ç·’è¡Œè®°ins é¡¶ç­†TENä½¿çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8od9ahed/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via. ç·’è¡Œè®°ins <!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Ohemcxw">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œvia.ä¹ƒæœ¨å‚46 tiktok [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8ohemcxw/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.ä¹ƒæœ¨å‚46 tiktok &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hojov4ictij31ey1w0kjl.jpg%22">https://tvax1.sinaimg.cn/large/006z6nxLgy1hojov4ictij31ey1w0kjl.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Pwqtrld">åŸæ¥å½“ä½ è¯´æƒ³è¦è§ä¸€ä¸ªäººåªè¦èƒ½è¯´å‡ºå£ï¼Œå¥¹ä¹Ÿä¼šæ„¿æ„è§ä½ æ€ä¹ˆä¸æ˜¯åŒå‘å¥”èµ´</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8pwqtrld/">
    
    
    
    
    
      
    
    åŸæ¥å½“ä½ è¯´æƒ³è¦è§ä¸€ä¸ªäºº<!-- raw HTML omitted -->åªè¦èƒ½è¯´å‡ºå£ï¼Œå¥¹ä¹Ÿä¼šæ„¿æ„è§ä½ <!-- raw HTML omitted -->æ€ä¹ˆä¸æ˜¯åŒå‘å¥”èµ´  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeAfMEf">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.08 21:03ã€Œå‘¼å‘¼å‘¼ã€å•Šï¼Œæˆ‘åœ¨çœ‹æ˜¨å¤©çš„æ¯”èµ›å“Ÿæ˜¨å¤©å› ä¸ºåœ¨å·¥ä½œæ²¡èƒ½çœ‹æ‰€ä»¥ç°åœ¨çœ‹ã€‚æˆ‘æœ€å¹¸ç¦...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qeafmef/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231">https://m.weibo.cn/search?containerid=231</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeDbZTv">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# .æ—¥å¤ä¸€æ—¥ã€‚ç°åœ¨å–œæ¬¢çš„è¯è¯­ã€‚æˆ‘çš„å–œæ¬¢çš„è¯è¯­ã€‚æ²¡æœ‰å“ªä¸€å¤©æ˜¯ç›¸åŒçš„ï¼Œæ¯å¤©éƒ½æ˜¯ç‰¹åˆ«çš„æ—¥å­ï¼Œæ‰€ä»¥æˆ‘ä¹Ÿæ›¾...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qedbztv/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?">https://m.weibo.cn/search?</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeL7pmJ">stä½ çœŸè¯¥æ­» - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œä¹…ä¿é…±æœ€åçš„ç•™è¨€âœ‰ï¸ğŸ’œä¸ºäº†å„ä½è¯»è€…ï¼Œè®©å¥¹æ‰‹å†™äº†ä¿¡ä»¶å“¦ã€‚æ¯ä¸€ä¸ªè¯è¯­éƒ½å¾ˆæ¸©æš–ï¼Œæ˜¯æœ‰ç€ä¹…ä¿é…±é£æ ¼çš„ç•™è¨€ğŸ˜Œç»™S...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qel7pmj/">
    
    
    
    
    
      
    
    stä½ çœŸè¯¥æ­»<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeNt58o">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# è¿™æ˜¯Seventeençš„æœ€åä¸€æ¬¡æ‹æ‘„çš„æ¨¡æ ·ã€‚è¯·ä¸€å®šè¦çœ‹å“¦ã€‚ğŸŒ· [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qent58o/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;am">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;am</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Qey6cKx">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.08 21:02ã€Œå‘¼å‘¼å‘¼ã€ä»Šå¤©æ™šå®‰äº†æˆ‘è¦ä»¥è‡ªå·±çš„é£æ ¼ï¼Œå»åšæˆ‘è¯¥åšçš„äº‹ï¼ä¼šå¥½å¥½åŠªåŠ›çš„å“¦ã€œæ™š...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qey6ckx/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t">https://m.weibo.cn/search?containerid=231522type%3D1%26t</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Kbieqr1">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œvia.seventeenjp_mag ins [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kbieqr1/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1hoj5q4j86bj30m80rs0ut.jpg%22">https://tvax4.sinaimg.cn/large/006z6nxLgy1hoj5q4j86bj30m80rs0ut.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Kf49BFp">æœˆç·’ ä¹…ä¿é†¬æ˜¯tenä½¿çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kf49bfp/">
    
    
    
    
    
      
    
    æœˆç·’ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿é†¬æ˜¯tenä½¿çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/GixlonFUlx08dUUCPuEU010412000PYZ0E010.mp4?label=mp4_h">https://f.video.weibocdn.com/o0/GixlonFUlx08dUUCPuEU010412000PYZ0E010.mp4?label=mp4_h</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8KgQ50T5">æ­£[å¤ªå¼€å¿ƒ][å¤ªå¼€å¿ƒ][å¤ªå¼€å¿ƒ] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kgq50t5/">
    
    
    
    
    
      
    
    æ­£<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8KVT3S8d">å¾ˆå¯æ„›è€¶//@The_Notorious_vo1d:è¿™å¼ å½“å†™çœŸé›†å°é¢æ•ˆæœæ¯”è¾ƒå¥½ - è½¬å‘ @The_Notorious_vo1d:&amp;ensp;#å±±ä¸‹ç¾æœˆ# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kvt3s8d/">
    
    
    
    
    
      
    
    å¾ˆå¯æ„›è€¶//<!-- raw HTML omitted -->@The_Notorious_vo1d<!-- raw HTML omitted -->:è¿™å¼ å½“å†™çœŸé›†å°é¢æ•ˆæœæ¯”è¾ƒå¥½<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@The_Notorious_vo1d<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->#å±±ä¸‹ç¾æœˆ#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8MmWAnLI">éƒ½æ˜¯ä¼‘æ¯å®¤çš„ä¸€ç˜ç™½é›ªäº†[å“ˆå“ˆ] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8mmwanli/">
    
    
    
    
    
      
    
    éƒ½æ˜¯ä¼‘æ¯å®¤çš„ä¸€ç˜ç™½é›ªäº†<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8NES8rsb">å˜Ÿå˜´ - è½¬å‘ @AyaTea:&amp;ensp;å‰ç”°ç»«ä¹ƒ#å‰ç”°ç»«ä¹ƒã‚¯ãƒªã‚¹ãƒ†ã‚£ãƒ¼##å‰ç”°ç»«ä¹ƒå…‹è‰ä¸è’‚# 35å•éŸ³ç•ªæˆå‘˜é—´åˆç…§ å‰ç”°ç»«ä¹ƒå…‹è‰ä¸è’‚éƒ¨åˆ†via.ä¹ƒæœ¨å‚46 Tiktok [å›¾ç‰‡][å›¾ç‰‡][å›¾...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8nes8rsb/">
    
    
    
    
    
      
    
    å˜Ÿå˜´<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@AyaTea<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å‰ç”°ç»«ä¹ƒ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E5%90%89%E7%94%B0%E7%BB%AB%E4%25B">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E5%90%89%E7%94%B0%E7%BB%AB%E4%B</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8OqXeUEa">å˜Ÿå˜´å¯æ„›ï¼ŒæŠ¿å˜´æ›´å¯æ„›[å“ˆå“ˆ] - è½¬å‘ @IRONæ¬§ç±³ä¼½:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œå£çº¸[é€èŠ±èŠ±] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8oqxeuea/">
    
    
    
    
    
      
    
    å˜Ÿå˜´å¯æ„›ï¼ŒæŠ¿å˜´æ›´å¯æ„›<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@IRONæ¬§ç±³ä¼½<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_defaul">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_defaul</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8MJjmgHm">ã€æ‚²æŠ¥ã€‘æ‰¾å€Ÿå£å®‰é™ï¼Œå¹´åˆè¯´å¥½ä¸€å‘¨4ç¯‡å·¦å³å°±å¥½ï¼Œè¿è½½ä¸€æå¼€å§‹è¢«è¿«æ—¥æ›´#å›´æ£‹#å›´æ£‹</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8mjjmghm/">
    
    
    
    
    
      
    
    ã€æ‚²æŠ¥ã€‘æ‰¾å€Ÿå£å®‰é™ï¼Œå¹´åˆè¯´å¥½ä¸€å‘¨4ç¯‡å·¦å³å°±å¥½ï¼Œè¿è½½ä¸€æå¼€å§‹è¢«è¿«æ—¥æ›´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å›´æ£‹<!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8NqwFegS">æˆªæ­¢è‡³4æœˆ4æ—¥çš„æ—¥æœ¬æ£‹æ‰‹å¤šèƒœæ¦œï¼ˆä¸åŒ…æ‹¬NHKæ¯å’Œé¾™æ˜Ÿæˆ˜çš„æˆ˜ç»©ï¼‰æ’åçš„å˜åŠ¨å¹…åº¦æ ¹æ®3æœˆ22æ—¥çš„æ’åè¿›è¡Œæ¯”è¾ƒ#å›´æ£‹#å›´æ£‹ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8nqwfegs/">
    
    
    
    
    
      
    
    æˆªæ­¢è‡³4æœˆ4æ—¥çš„æ—¥æœ¬æ£‹æ‰‹å¤šèƒœæ¦œï¼ˆä¸åŒ…æ‹¬NHKæ¯å’Œé¾™æ˜Ÿæˆ˜çš„æˆ˜ç»©ï¼‰<!-- raw HTML omitted --><!-- raw HTML omitted -->æ’åçš„å˜åŠ¨å¹…åº¦æ ¹æ®3æœˆ22æ—¥çš„æ’åè¿›è¡Œæ¯”è¾ƒ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8NZnuFYJ">æ£‹æ‰‹æˆ˜é¹°1å·çš„æ„ä¹‰é‡å¤§[äºŒå“ˆ] [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8nznufyj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æ£‹æ‰‹æˆ˜é¹°<!-- raw HTML omitted --><!-- raw HTML omitted -->1å·çš„æ„ä¹‰é‡å¤§<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8PbmEofW">å‘å¸ƒäº†å¤´æ¡æ–‡ç« ï¼šã€Šå–œå¤šæ–‡å­ï¼šæ—¥æœ¬å›´æ£‹ç•Œä¹‹æ¯â€”â€”æ—¥æœ¬å›´æ£‹ç™¾å¤§å¥ åŸºäºº007ã€‹ #å›´æ£‹# å›´æ£‹ å–œå¤šæ–‡å­ï¼šæ—¥æœ¬å›´æ£‹ç•Œä¹‹æ¯â€”â€”æ—¥æœ¬å›´æ£‹ç™¾å¤§å¥ åŸºäºº007 [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8pbmeofw/">
    
    
    
    
    
      
    
    å‘å¸ƒäº†å¤´æ¡æ–‡ç« ï¼šã€Šå–œå¤šæ–‡å­ï¼šæ—¥æœ¬å›´æ£‹ç•Œä¹‹æ¯â€”â€”æ—¥æœ¬å›´æ£‹ç™¾å¤§å¥ åŸºäºº007ã€‹ <!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å›´æ£‹<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8Jug0gar">ä¹…ä¿å²ç»ªé‡Œvia.seventeenjp_mag ins [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8jug0gar/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1h">https://tvax4.sinaimg.cn/large/006z6nxLgy1h</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8MsdocSS">ä¹…ä¿å²ç»ªé‡Œvia.nogizaka_goods X2024å¹´4æœˆéšæœºç”Ÿå†™ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8msdocss/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.nogizaka_goods X<!-- raw HTML omitted -->2024å¹´4æœˆéšæœºç”Ÿå†™ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8N3e1SBJ">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.08 19:10ã€Œå‘œå‘¼å‘¼ã€æ˜¯æƒ³åŠªåŠ›çš„æ—¥å­å‘¢ã€œè™½ç„¶å¤©æ°”ä¸å¤ªç¨³å®šï¼Œä½†ä¸è¦è¢«è¿™å·¦å³ï¼Œè†å¬å–œæ¬¢çš„éŸ³ä¹ï¼Œå“å°å–œæ¬¢çš„é£Ÿç‰©ï¼Œå–œæ¬¢çš„äººåˆ™...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8n3e1sbj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8N7Ay8M3">ä¹…ä¿å²ç»ªé‡Œvia. ç·’è¡Œè®°ins é¡¶ç­†TENä½¿çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8n7ay8m3/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via. ç·’è¡Œè®°ins <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/time">https://h5.sinaimg.cn/upload/2015/09/25/3/time</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8NP1DRf1">ä¹…ä¿å²ç»ªé‡Œvia.ä¹ƒæœ¨å‚46 tiktok [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8np1drf1/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.ä¹ƒæœ¨å‚46 tiktok <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/006z6nxLgy1hoj">https://tvax3.sinaimg.cn/large/006z6nxLgy1hoj</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PCIyAiT">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.08 21:02ã€Œå‘¼å‘¼å‘¼ã€ä»Šå¤©æ™šå®‰äº†æˆ‘è¦ä»¥è‡ªå·±çš„é£æ ¼ï¼Œå»åšæˆ‘è¯¥åšçš„äº‹ï¼ä¼šå¥½å¥½åŠªåŠ›çš„å“¦ã€œæ™šå®‰ï¼æ„Ÿè§‰èƒ½æ—¶éš”è®¸ä¹…åœ°ç¡å¾—å¾ˆæ²‰ï¼å¤§...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pciyait/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;am">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;am</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PCSwYtM">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.04.08 21:03ã€Œå‘¼å‘¼å‘¼ã€å•Šï¼Œæˆ‘åœ¨çœ‹æ˜¨å¤©çš„æ¯”èµ›å“Ÿæ˜¨å¤©å› ä¸ºåœ¨å·¥ä½œæ²¡èƒ½çœ‹æ‰€ä»¥ç°åœ¨çœ‹ã€‚æˆ‘æœ€å¹¸ç¦çš„æ—¶é—´ã€‚å½“ç„¶å¾ˆæƒ³é›†ä¸­ç²¾ç¥çœ‹å•¦â€¦ä½†...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pcswytm/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PD9h1La">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# .æ—¥å¤ä¸€æ—¥ã€‚ç°åœ¨å–œæ¬¢çš„è¯è¯­ã€‚æˆ‘çš„å–œæ¬¢çš„è¯è¯­ã€‚æ²¡æœ‰å“ªä¸€å¤©æ˜¯ç›¸åŒçš„ï¼Œæ¯å¤©éƒ½æ˜¯ç‰¹åˆ«çš„æ—¥å­ï¼Œæ‰€ä»¥æˆ‘ä¹Ÿæ›¾æƒ³è¿‡ï¼Œè¿™æ ·æ±‡æ€»æˆä¸€ä¸ªè¯è¯­åˆ°åº•å¥½ä¸å¥½...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pd9h1la/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;amp;extparam=%23shiorigram%23%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;amp;extparam=%23shiorigram%23&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PJU7Afh">ä¹…ä¿å²ç»ªé‡Œä¹…ä¿é…±æœ€åçš„ç•™è¨€âœ‰ï¸ğŸ’œä¸ºäº†å„ä½è¯»è€…ï¼Œè®©å¥¹æ‰‹å†™äº†ä¿¡ä»¶å“¦ã€‚æ¯ä¸€ä¸ªè¯è¯­éƒ½å¾ˆæ¸©æš–ï¼Œæ˜¯æœ‰ç€ä¹…ä¿é…±é£æ ¼çš„ç•™è¨€ğŸ˜Œç»™Seventeençš„å„ä½è¯»è€…çº¦6å¹´åŠä»¥æ¥ï¼ŒçœŸçš„...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pju7afh/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿é…±æœ€åçš„ç•™è¨€âœ‰ï¸ğŸ’œ<!-- raw HTML omitted -->ä¸ºäº†å„ä½è¯»è€…ï¼Œè®©å¥¹æ‰‹å†™äº†ä¿¡ä»¶å“¦ã€‚æ¯ä¸€ä¸ªè¯è¯­éƒ½å¾ˆæ¸©æš–ï¼Œæ˜¯æœ‰ç€ä¹…ä¿é…±é£æ ¼çš„ç•™è¨€ğŸ˜Œ<!-- raw HTML omitted -->&lt;b &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PK5dv6N">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# è¿™æ˜¯Seventeençš„æœ€åä¸€æ¬¡æ‹æ‘„çš„æ¨¡æ ·ã€‚è¯·ä¸€å®šè¦çœ‹å“¦ã€‚ğŸŒ· [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pk5dv6n/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram#<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8Oism1JF">æŸ¯æ´ ç»™å¥½æœ‹å‹è¿‡ç”Ÿæ—¥çš„æŸ¯æŸ¯ï½[é€èŠ±èŠ±] - è½¬å‘ @æ¨æ¥·æ–‡-:&amp;ensp;@è¿ç¬‘ 20å²ç”Ÿæ—¥å¿«ä¹ğŸ‚ğŸ‚ è¡¢å· [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8oism1jf/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --> ç»™å¥½æœ‹å‹è¿‡ç”Ÿæ—¥çš„æŸ¯æŸ¯ï½<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8OUR4sYe">æŸ¯æ´#2024lgæ¯é€‰æ‹”èµ›##èµ›äº‹é¢„å‘Š# ç¬¬29å±ŠLGæ¯ä¸–ç•Œå›´æ£‹æ£‹ç‹æˆ˜ä¸­å›½ä»£è¡¨é€‰æ‹”èµ›ç¬¬ä¸€é˜¶æ®µå°†äº4æœˆ9æ—¥ã€10æ—¥ã€12æ—¥ä¸­åˆåäºŒç‚¹åŠåœ¨æµ™æ±Ÿè¡¢å·å—å­”è§‚å ‚é…’åº—è¿›è¡Œï¼ŒæŸ¯æ´ä¹æ®µé¦–...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8our4sye/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1aZ421e79K">ä¸‹å†°é›¹çš„å¤œæ™šï¼Œè·Ÿç‹—é—ºèœœååœ¨æ‘å£èŠå¤©ï¼Œè¿™ä»½å‹æƒ…åƒé‡‘éš¾ä¹°å“¦</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1az421e79k/">
    
    
    
    
    
      
    
    ä¸‹å†°é›¹çš„å¤œæ™šï¼Œè·Ÿç‹—é—ºèœœååœ¨æ‘å£èŠå¤©ï¼Œè¿™ä»½å‹æƒ…åƒé‡‘éš¾ä¹°å“¦<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1Gx4y1Y7cJ">ã€ç›´æ’­å›æ”¾ã€‘å˜Ÿå˜Ÿåƒé¥­é¥­å’¯ï¼ 2024å¹´4æœˆ8æ—¥19ç‚¹åœº</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1gx4y1y7cj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1KT421m7RT">é™ˆç¿”å…­ç‚¹åŠï¼šä»¤äººå´©æºƒçš„å¦ç™½å±€ï¼Œè¿˜æœ‰ä»€ä¹ˆæ˜¯æˆ‘ä¸çŸ¥é“çš„</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1kt421m7rt/">
    
    
    
    
    
      
    
    å½“ä½ çš„å¥³æœ‹å‹æœ‰ç§˜å¯†æ—¶&hellip;<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1om411z7Ln">æˆ‘ä¸€å®šè¦æ‹¯æ•‘æˆ‘å“¥å“¥ï¼ï¼ï¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1om411z7ln/">
    
    
    
    
    
      
    
    -<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1yt421E7im">ç¾é£Ÿæ˜¯ç›¸é€¢æœ€å¥½çš„ç†ç”±ï¼Œç®€ç®€å•å•åšä¸ªé“æ¡¶çƒ¤å…¨ç¾Šï¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1yt421e7im/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/pin/1760620534143180801">é‡å­ä½å‘å¸ƒäº†æƒ³æ³•: é‡‘å±±åŠå…¬å‰¯æ€»è£å§šå†¬ ç¡®è®¤å‚ä¸ &lt;a class=&#34;hash_tag&#34; href=&#34;https://www.zhihu.com/topic/27243576&#34; data-pin-topic=&#34;zhihu://topic/27243576/p...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-pin-1760620534143180801/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/pin/1760757887067172865">é‡å­ä½å‘å¸ƒäº†æƒ³æ³•: èš‚èšé›†å›¢ä»£ç å¤§æ¨¡å‹CodeFuseè´Ÿè´£äººæå»ºå›½ ç¡®è®¤å‚ä¸ #ä¸­å›½AIGCäº§ä¸šå³°ä¼š ï¼ğŸ”¥&lt;br&gt;&lt;br&gt;æå»ºå›½åšå£«æ·±è€•æœºå™¨å­¦ä¹ ã€æ·±åº¦å­¦ä¹ é¢†åŸŸå¤šå¹´ï¼Œåœ¨ç›¸å…³é¡¶ä¼š...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-pin-1760757887067172865/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/651930592/answer/3458734195">å¼ æ•¬ä¿¡å›ç­”äº†é—®é¢˜: è¯·é—®å¦‚ä½•åœ¨excelä¸­è‡ªåŠ¨ç”Ÿæˆæ¯ä¸ªå­—å‡ºç°çš„æ¬¡æ•°ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-651930592-answer-3458734195/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691083149">é‡å­ä½å‘è¡¨äº†æ–‡ç« : é˜¿é‡Œåˆšå¼€æº32Bå¤§æ¨¡å‹ï¼Œæˆ‘ä»¬ç«‹é©¬æµ‹è¯•äº†â€œå¼±æ™ºå§â€</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691083149/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691250731">é‡å­ä½å‘è¡¨äº†æ–‡ç« : â€œéŸ³ä¹ç‰ˆSoraâ€é¦–æ‰¹æ¼”ç¤ºæ³„éœ²ï¼Œç½‘å‹ï¼šæ¯”å†™ã€Šå®«ä¿é¸¡ä¸ã€‹çš„Sunoå¥½10å€</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691250731/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691258824">é‡å­ä½å‘è¡¨äº†æ–‡ç« : é™¶å“²è½©è½¬å‘ã€è²å°”å…¹å¥–å¾—ä¸»é¢†è¡”ï¼šAIæ­£åœ¨é¢ è¦†æ•°å­¦å®¶çš„å·¥ä½œæ–¹å¼ | ç¾å›½æ•°å­¦å­¦ä¼šç‰¹åˆŠ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691258824/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691264949">é‡å­ä½å‘è¡¨äº†æ–‡ç« : åŒ—å¤§&amp;ç«å±±å¼•æ“å¤ºå† ï¼CLICè§†é¢‘å‹ç¼©æŒ‘æˆ˜èµ›ç»“æœå…¬å¸ƒï¼Œä¸­å›½å›¢é˜Ÿè¡¨ç°äº®çœ¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691264949/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691268834">é‡å­ä½å‘è¡¨äº†æ–‡ç« : ç¬¬ä¸€ä¸ªèƒ½å¬æ‡‚äººç±»è¯­æ°”çš„AIç«äº†ï¼Œç½‘å‹ï¼šæ„Ÿè§‰åœ¨å’ŒçœŸäººäº¤è°ˆ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691268834/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

